Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:16 pm EDT
Share
Vaxart, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 2.1 million. Net loss was USD 17.4 million compared to USD 29.31 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.23 a year ago.
For the nine months, revenue was USD 4.13 million compared to USD 0.085 million a year ago. Net loss was USD 65.09 million compared to USD 83.84 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.66 a year ago. Diluted loss per share from continuing operations was USD 0.45 compared to USD 0.66 a year ago.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
VAXART, INC. 
